ME02297B - UNITS WHICH HAVE THE ACTIVITY OF MUSCARINE RECEPTOR ANTAGONISTS AND THE ADRENERGIC RECEPTOR AGONIST BETA2 - Google Patents

UNITS WHICH HAVE THE ACTIVITY OF MUSCARINE RECEPTOR ANTAGONISTS AND THE ADRENERGIC RECEPTOR AGONIST BETA2

Info

Publication number: ME02297B
Authority: ME; Montenegro
Prior art keywords: beta2; activity; units; muscarine; receptor antagonists
Prior art date: 2011-06-10

Application number

MEP-2015-187A

Other languages

Unknown language (me)

Inventor

Fabio Rancati

Andrea Rizzi

Gabriele Amari

Matteo Biagetti

Ian Linney

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-10

Filing date

2012-06-07

Publication date

2016-02-20

2012-06-07 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2016-02-20 Publication of ME02297B publication Critical patent/ME02297B/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MEP-2015-187A 2011-06-10 2012-06-07 UNITS WHICH HAVE THE ACTIVITY OF MUSCARINE RECEPTOR ANTAGONISTS AND THE ADRENERGIC RECEPTOR AGONIST BETA2 ME02297B (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP11169537		2011-06-10
EP12165283		2012-04-24
EP12730176.0A EP2718280B1 (en)	2011-06-10	2012-06-07	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PCT/EP2012/060795 WO2012168359A1 (en)	2011-06-10	2012-06-07	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number	Publication Date
ME02297B true ME02297B (en)	2016-02-20

Family

ID=46395589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2015-187A ME02297B (en)	2011-06-10	2012-06-07	UNITS WHICH HAVE THE ACTIVITY OF MUSCARINE RECEPTOR ANTAGONISTS AND THE ADRENERGIC RECEPTOR AGONIST BETA2

Country Status (32)

Country	Link
US (1)	US8877774B2 (en)
EP (1)	EP2718280B1 (en)
JP (1)	JP6080051B2 (en)
KR (1)	KR101944564B1 (en)
CN (1)	CN103562198B (en)
AR (1)	AR088023A1 (en)
AU (1)	AU2012266378B2 (en)
BR (1)	BR112013031493B1 (en)
CA (1)	CA2838765C (en)
CL (1)	CL2013003527A1 (en)
CO (1)	CO6821950A2 (en)
CY (1)	CY1116892T1 (en)
DK (1)	DK2718280T3 (en)
EA (1)	EA022342B1 (en)
ES (1)	ES2552538T3 (en)
HR (1)	HRP20151317T1 (en)
HU (1)	HUE027000T2 (en)
IL (1)	IL229867A (en)
MA (1)	MA35187B1 (en)
ME (1)	ME02297B (en)
MX (1)	MX346559B (en)
MY (1)	MY169479A (en)
PE (1)	PE20141614A1 (en)
PH (1)	PH12013502551A1 (en)
PL (1)	PL2718280T3 (en)
PT (1)	PT2718280E (en)
RS (1)	RS54365B1 (en)
SG (1)	SG195375A1 (en)
SI (1)	SI2718280T1 (en)
TW (1)	TWI596094B (en)
WO (1)	WO2012168359A1 (en)
ZA (1)	ZA201309242B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITRM20110083U1 (en)	2010-05-13	2011-11-14	De La Cruz Jose Antonio Freire	PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2386555A1 (en)	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2012168349A1 (en)	2011-06-10	2012-12-13	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2592078A1 (en)	2011-11-11	2013-05-15	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
AR093832A1 (en) *	2012-12-06	2015-06-24	Chiesi Farm Spa	COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEPTORS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2
PT2928889T (en) *	2012-12-06	2018-05-29	Chiesi Farm Spa	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AP2015008573A0 (en)	2012-12-18	2015-07-31	Almirall Sa	New cyclohexyl and quinuclidinyl carbamate derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonsit activity
TWI643853B (en)	2013-02-27	2018-12-11	阿爾米雷爾有限公司	a salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activity
TWI641373B (en)	2013-07-25	2018-11-21	阿爾米雷爾有限公司	Salt of 2-amino-1-hydroxyethyl-8-hydroxyquinoline-2(1H)-one derivative having activity of both a muscarinic receptor antagonist and a β2 adrenergic receptor agonist
TW201517906A (en)	2013-07-25	2015-05-16	Almirall Sa	Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) *	2014-09-26	2016-05-16	阿爾米雷爾有限公司	New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
TWI703138B (en)	2015-02-12	2020-09-01	義大利商吉斯藥品公司	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AR104828A1 (en)	2015-06-01	2017-08-16	Chiesi Farm Spa	COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEIVERS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2
EP3383867B1 (en)	2015-12-03	2021-04-14	Chiesi Farmaceutici S.p.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3484879B1 (en)	2016-07-13	2020-12-30	Chiesi Farmaceutici S.p.A.	Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP6963616B2 (en)	2016-12-14	2021-11-10	ベイジンショウバイファーマシューティカルカンパニー，リミティッド	Bifunctional compound having a quaternary ammonium salt structure
CN108456213B (en) *	2017-02-22	2021-01-15	浙江九洲药业股份有限公司	Preparation method of 3-fluoro-4-hydroxycyclohexane carboxylate
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HRP20221196T1 (en)	2017-10-05	2022-12-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
CN110343068B (en) *	2018-04-04	2022-02-11	沈阳药科大学	2-amino-2-quinolyl ethanol beta 2-receptor agonist and preparation method and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4983771A (en) *	1989-09-18	1991-01-08	Hexcel Corporation	Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
EP0564397A1 (en) *	1992-03-03	1993-10-06	Sandoz Ltd.	Antiatherosclerotic substituted phenylquinazoline derivatives
FR2783246B1 (en) *	1998-09-11	2000-11-17	Aventis Pharma Sa	AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
DE19921693A1 (en)	1999-05-12	2000-11-16	Boehringer Ingelheim Pharma	Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US6417367B1 (en) *	2000-08-11	2002-07-09	Pfizer Inc.	Methods of making quinoline amides
JP2004059492A (en) *	2002-07-29	2004-02-26	Sumitomo Chem Co Ltd	Method for producing optically active α- (2-aminophenyl) benzylamine
CA2499314C (en)	2002-10-11	2010-08-24	Pfizer Inc.	Indole derivatives as beta-2 agonists
PE20040950A1 (en)	2003-02-14	2005-01-01	Theravance Inc	BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
DE602004021959D1 (en)	2003-11-21	2009-08-20	Theravance Inc	COMPOUNDS OF AGONISTIC EFFECT ON THE BETA2 ADRENEER RECEPTOR AND THE MUSCARIN RECIPE
GEP20084452B (en)	2004-01-22	2008-08-10	Pfizer	Sulfonamide derivatives for the treatment of diseases
WO2005092861A1 (en)	2004-03-11	2005-10-06	Pfizer Limited	Quinolinone derivatives pharmaceutical compositions containing them and their use
WO2005092840A1 (en)	2004-03-23	2005-10-06	Pfizer Limited	Formamide derivatives useful as adrenoceptor
US7538141B2 (en)	2004-03-23	2009-05-26	Alan Daniel Brown	Compounds for the treatment of diseases
ES2257152B1 (en)	2004-05-31	2007-07-01	Laboratorios Almirall S.A.	COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
WO2006023460A2 (en)	2004-08-16	2006-03-02	Theravance, Inc.	COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
US7528253B2 (en)	2004-08-16	2009-05-05	Theravance, Inc.	Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
FR2898640B1 (en)	2006-03-20	2008-04-25	Siemens Vdo Automotive Sas	METHOD FOR TRANSMITTING INFORMATION RELATING TO THE OPERATION OF AN INTERNAL COMBUSTION ENGINE
GB0613154D0 (en) *	2006-06-30	2006-08-09	Novartis Ag	Organic Compounds
WO2008096129A1 (en) *	2007-02-07	2008-08-14	Argenta Discovery Ltd	Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
EP2080523A1 (en) *	2008-01-15	2009-07-22	CHIESI FARMACEUTICI S.p.A.	Compositions comprising an antimuscarinic and a long-acting beta-agonist
DK2421849T3 (en)	2009-04-23	2013-07-01	Theravance Inc	Diamide compounds with muscarinic receptor antagonist and beta2-adrenoreceptor agonist activity
BRPI1014390A2 (en) *	2009-04-30	2016-04-05	Teijin Pharma Ltd	quaternary ammonium salt compound, medicinal composition, and preventative or therapeutic agent
WO2011048409A1 (en)	2009-10-20	2011-04-28	Astrazeneca Ab	Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

2012
- 2012-06-07 KR KR1020137032136A patent/KR101944564B1/en active IP Right Grant
- 2012-06-07 PT PT127301760T patent/PT2718280E/en unknown
- 2012-06-07 SG SG2013091038A patent/SG195375A1/en unknown
- 2012-06-07 DK DK12730176.0T patent/DK2718280T3/en active
- 2012-06-07 ES ES12730176.0T patent/ES2552538T3/en active Active
- 2012-06-07 EA EA201391662A patent/EA022342B1/en unknown
- 2012-06-07 ME MEP-2015-187A patent/ME02297B/en unknown
- 2012-06-07 PL PL12730176T patent/PL2718280T3/en unknown
- 2012-06-07 CA CA2838765A patent/CA2838765C/en active Active
- 2012-06-07 WO PCT/EP2012/060795 patent/WO2012168359A1/en active Application Filing
- 2012-06-07 RS RS20150744A patent/RS54365B1/en unknown
- 2012-06-07 PE PE2013002744A patent/PE20141614A1/en active IP Right Grant
- 2012-06-07 AU AU2012266378A patent/AU2012266378B2/en not_active Ceased
- 2012-06-07 CN CN201280025213.9A patent/CN103562198B/en active Active
- 2012-06-07 JP JP2014514068A patent/JP6080051B2/en active Active
- 2012-06-07 PH PH1/2013/502551A patent/PH12013502551A1/en unknown
- 2012-06-07 MY MYPI2013004418A patent/MY169479A/en unknown
- 2012-06-07 SI SI201230362T patent/SI2718280T1/en unknown
- 2012-06-07 BR BR112013031493-1A patent/BR112013031493B1/en active IP Right Grant
- 2012-06-07 MX MX2013013786A patent/MX346559B/en active IP Right Grant
- 2012-06-07 EP EP12730176.0A patent/EP2718280B1/en active Active
- 2012-06-07 HU HUE12730176A patent/HUE027000T2/en unknown
- 2012-06-08 AR ARP120102064A patent/AR088023A1/en active IP Right Grant
- 2012-06-08 TW TW101120664A patent/TWI596094B/en not_active IP Right Cessation
- 2012-06-08 US US13/492,458 patent/US8877774B2/en active Active
2013
- 2013-12-09 ZA ZA2013/09242A patent/ZA201309242B/en unknown
- 2013-12-09 IL IL229867A patent/IL229867A/en active IP Right Grant
- 2013-12-09 CL CL2013003527A patent/CL2013003527A1/en unknown
- 2013-12-09 CO CO13287756A patent/CO6821950A2/en active IP Right Grant
- 2013-12-17 MA MA36576A patent/MA35187B1/en unknown
2015
- 2015-10-30 CY CY20151100973T patent/CY1116892T1/en unknown
- 2015-12-03 HR HRP20151317TT patent/HRP20151317T1/en unknown

Also Published As

Publication number	Publication date
JP6080051B2 (en)	2017-02-15
PL2718280T3 (en)	2016-03-31
EP2718280B1 (en)	2015-09-16
US8877774B2 (en)	2014-11-04
PH12013502551A1 (en)	2015-11-06
ZA201309242B (en)	2015-05-27
MA35187B1 (en)	2014-06-02
CN103562198A (en)	2014-02-05
KR20140033076A (en)	2014-03-17
AU2012266378B2 (en)	2017-03-02
EA201391662A1 (en)	2014-03-31
MX2013013786A (en)	2013-12-16
SG195375A1 (en)	2013-12-30
CL2013003527A1 (en)	2014-08-08
IL229867A (en)	2016-06-30
BR112013031493A2 (en)	2016-12-27
CY1116892T1 (en)	2017-04-05
US20130045169A1 (en)	2013-02-21
BR112013031493B1 (en)	2022-04-19
PE20141614A1 (en)	2014-11-20
RS54365B1 (en)	2016-04-28
HRP20151317T1 (en)	2016-01-01
NZ618727A (en)	2016-01-29
EP2718280A1 (en)	2014-04-16
PT2718280E (en)	2015-11-25
HUE027000T2 (en)	2016-08-29
WO2012168359A1 (en)	2012-12-13
CA2838765C (en)	2019-05-07
TW201302729A (en)	2013-01-16
TWI596094B (en)	2017-08-21
SI2718280T1 (en)	2015-12-31
MX346559B (en)	2017-03-24
AR088023A1 (en)	2014-05-07
CA2838765A1 (en)	2012-12-13
ES2552538T3 (en)	2015-11-30
CO6821950A2 (en)	2013-12-31
CN103562198B (en)	2016-08-24
AU2012266378A1 (en)	2014-01-09
EA022342B1 (en)	2015-12-30
MY169479A (en)	2019-04-15
JP2014519508A (en)	2014-08-14
KR101944564B1 (en)	2019-01-31
DK2718280T3 (en)	2016-01-11

Publication	Publication Date	Title
ME02297B (en)	2016-02-20	UNITS WHICH HAVE THE ACTIVITY OF MUSCARINE RECEPTOR ANTAGONISTS AND THE ADRENERGIC RECEPTOR AGONIST BETA2
CY2023022I1 (en)	2024-02-16	PIPERIDINONE AZAINDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS
FR22C1044I1 (en)	2022-09-30	CGRP RECEPTOR ANTAGONISTS
RS57232B1 (en)	2018-07-31	UNITS WHICH HAVE MUSCARIAN RECEPTORS OF ANTAGONIST ACTIVITY AND BETA2 ADRENERGIK RECEPTORS OF AGONIST ACTIVITY
SMT201600078B (en)	2016-04-29	ANTAGONIST OF THE CGRP RECEPTOR
EP2911675A4 (en)	2016-06-01	ANTAGONISTS OF THE 2-PYRIDYLOXY-3-SUBSTITUTED-4-NITRILE OREXIN RECEPTOR
EP2908812A4 (en)	2016-04-20	ANTAGONISTS OF 2-PYRIDYLOXY-3-ESTER-4-NITRILE TYPE OF OREXIN RECEPTORS
PL2928890T3 (en)	2018-07-31	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112013009636A2 (en)	2016-07-19	chemosensory receptor ligand-based therapies
EP2665707A4 (en)	2015-01-14	Mineralocorticoid receptor antagonists
DK3170501T3 (en)	2020-09-28	ANTAGONISTS OF CB1 RECEPTOR
DK3312169T3 (en)	2021-12-13	5-HT3 RECEPTOR ANTAGONISTS
EP2709991A4 (en)	2014-10-01	USE OF CXCR4 ANTAGONISTS
IL250606A0 (en)	2017-04-30	d2 antagonists, methods of synthesis and methods of use
HUE063115T2 (en)	2023-12-28	Chimeric type I IL-1 receptor antagonists
ZA201306744B (en)	2014-11-26	Antagonists of the interleukin-1 receptor
EP2654423A4 (en)	2014-05-28	AZAINDANE ANTAGONISTS HETEROCYCLIC CARBOXAMIDES MERGED FROM CGRP RECEPTORS
SMT201500296B (en)	2016-01-08	ANTAGONISTS OF THE TRPM8 RECEPTOR
EP2578569A4 (en)	2014-01-15	HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST
EP2539706A4 (en)	2013-07-31	ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
EP2408304A4 (en)	2012-12-12	CGRP RECEPTOR ANTAGONISTS
EP2846800A4 (en)	2015-11-11	HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
CO6821933A2 (en)	2013-12-31	Non-competitive nicotinic receptor antagonists